✦ LIBER ✦

Regulatory considerations for preclinical development of anticancer drugs

✍ Scribed by Joseph J. DeGeorge; Chang-Ho Ahn; Paul A. Andrews; Margaret E. Brower; Diana W. Giorgio; M. Anwar Goheer; Doo Y. Lee-Ham; W. David McGuinn; Wendelyn Schmidt; C. Joseph Sun; Satish C. Tripathi

Publisher: Springer
Year: 1997
Tongue: English
Weight: 193 KB
Volume: 41
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050726

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacogenetics in drug development: Re

Pharmacogenetics in drug development: Regulatory and clinical considerations

✍ Susan T. Hall; Neil Abbott; Ginny Schmith; Celia Brazell 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

Enantiomeric drug development: Issues, c

Enantiomeric drug development: Issues, considerations, and regulatory requirements

✍ Nuggehally R. Srinivas; Rashmi H. Barbhaiya; Kamal K. Midha 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB

Duchenne muscular dystrophy: Drug develo

Duchenne muscular dystrophy: Drug development and regulatory considerations

✍ D. Elizabeth McNeil; Carole Davis; Devanand Jillapalli; Shari Targum; Anthony Du 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

Strategy for the development of novel an

Strategy for the development of novel anticancer drugs

✍ Nagahiro Saijo; Tomohide Tamura; Kazuto Nishio 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 170 KB

The development of new anticancer drugs

✍ F. M. Arcamone 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 259 KB

Cell microarray platform for anticancer

Cell microarray platform for anticancer drug development

✍ Min-Jung Lee; Eun Joo Chung; Sunmin Lee; Joon-Yong Chung; William G. Telford; Ed 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB